Schema-ECT: A novel treatment for severe depressio

Completed

• Conditions: Major depressive disorder; Depression; 10027946

• Registration Number: NL-OMON41362
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 98

Inclusion Criteria

-Major depressive disorder (MDD) without psychotic symptoms
-Clinical indication for ECT
-18-70 years of age

Exclusion Criteria

-Bipolar disorder, schizophrenia, primary alcohol or drug abuse, or any cognitive disorder

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Treatment efficacy as measured with the Hamilton Rating Scale for Depression<br /><br>(HAM-D; 17-items). Response is defined as a 50% reduction and remission as a<br /><br>score <=7. The influence on negative schemas is measured with the Dysfunctional<br /><br>Attitude Scale (DAS), the Automatic Thoughts Questionnaire (ATQ), and the<br /><br>Self-Referent Encoding Task (SRET).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-Hippocampal magnetic resonance spectroscopy (MRS)<br /><br>-Structural connectivity using diffusion tensor imaging (DTI)<br /><br>-Functional connectivity using functional magnetic resonance imaging (fMRI)<br /><br>-Dopaminergic (dys-)function measured by a functional MRI of a probabilistic<br /><br>reward-related learning task (UMCG only)<br /><br>-Biomarker levels determined from blood samples</p><br>